Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3CHRM1CHRM2CHRM3CHRM4ESR1ESR2GABRA1GABRB1GABRG2GBA1HRH1HTR1DHTR2AOPRD1OPRK1OPRM1SLC6A2SLC6A3TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8rplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Cadaverine Tartrate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.83 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
| ▸ | PDE4A | P27815 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.35 |
| ▸ | F2 | P00734 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cadaverine Tartrate SCHEMBL741942 | 0.96 | TSHR (0.91) | TSHRTP53CYP2C9PDE4ACYP2C19 | |
| Cadaverine Tartrate SCHEMBL8054016 | 0.96 | TSHR (0.91) | TSHRTP53CYP2C9PDE4ACYP2C19 | |
| Cadaverine Tartrate SCHEMBL568517 | 0.96 | TSHR (0.91) | TSHRTP53CA1CA2CA9 | |
| Cadaverine Tartrate SCHEMBL8051107 | 0.96 | TSHR (0.91) | TSHRTP53CYP2C9PDE4ACYP2C19 | |
| Cadaverine Tartrate SCHEMBL18010561 | 0.96 | TSHR (0.91) | TSHRTP53CYP2C9PDE4ACYP2C19 | |
| Cadaverine Tartrate SCHEMBL28556371 | 0.96 | TSHR (0.91) | TSHRTP53CYP2C9PDE4ACYP2C19 | |
| Cadaverine Tartrate SCHEMBL80797 | 0.96 | TSHR (0.91) | TSHRTP53CYP2C9PDE4ACYP2C19 | |
| Cadaverine Tartrate SCHEMBL8766096 | 0.92 | TSHR (0.83) | TSHRTP53CYP2C9PDE4ACYP2C19 | |
| Cadaverine Tartrate SCHEMBL11224450 | 0.92 | TSHR (0.83) | TSHRTP53CYP2C9PDE4ACYP2C19 | |
| Cadaverine Tartrate SCHEMBL4953535 | 0.92 | TSHR (0.83) | TSHRTP53CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114306271-B | Lunvatinib composition | 石药集团中奇制药技术（石家庄）有限公司 | 2023-04-07 | — | — | CN | claimed |
| CN-114306271-A | Lunvatinib composition | 石药集团中奇制药技术（石家庄）有限公司 | 2022-04-12 | — | — | CN | claimed |
| CN-114306271-B | Lunvatinib composition | 石药集团中奇制药技术（石家庄）有限公司 | 2023-04-07 | — | — | CN | disclosed |
| CN-114306271-A | Lunvatinib composition | 石药集团中奇制药技术（石家庄）有限公司 | 2022-04-12 | — | — | CN | disclosed |
| CN-111670171-A | Decorative coating with improved IR reflection | 肖特股份有限公司 | 2020-09-15 | — | — | CN | disclosed |
| US-10251909-B2 | Potassium-magnesium citrate as a surrogate of the DASH diet in managing hypertension | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2019-04-09 | — | — | US | disclosed |
| US-20080193525-A1 | A mixture of potassium citrate and magnesium citrate; antidiabetic agents, diuretics, metabolic disorders; uric acid and calcium stones, hypokalemia, hypomagnesemia; side effect reduction | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2008-08-14 | — | — | US | disclosed |
| CN-1237061-C | Chemokine receptor binding heterocyclic compounds | ANORMED INC (CA) | 2006-01-18 | — | — | CN | disclosed |
| CN-1458929-A | Chemokine receptor binding heterocyclic compounds | ANORMED INC (CA) | 2003-11-26 | — | — | CN | disclosed |
| EP-0565668-B1 | BIOLOGICAL STAIN COMPOSITION, METHOD OF PREPARATION AND METHOD OF USE FOR DELINEATION OF EPITHELEAL CANCER | ZILA INC (US) | 1999-06-23 | — | — | EP | disclosed |
| US-5372801-A | Improved shelf stability, clinical consistency, and flavor using toluidine blue | CTM ASSOCIATES, INC. (US) | 1994-12-13 | — | — | US | disclosed |
| EP-0565668-A4 | BIOLOGICAL STAIN COMPOSITION, METHOD OF PREPARATION AND METHOD OF USE FOR DELINEATION OF EPITHELEAL CANCER | CTM ASS INC (US) | 1994-09-07 | — | — | EP | disclosed |
| EP-0565668-A1 | BIOLOGICAL STAIN COMPOSITION, METHOD OF PREPARATION AND METHOD OF USE FOR DELINEATION OF EPITHELEAL CANCER | Zila Inc. (US) | 1993-10-20 | — | — | EP | disclosed |
| WO-1993008847-A1 | BIOLOGICAL STAIN COMPOSITION, METHOD OF PREPARATION AND METHOD OF USE FOR DELINEATION OF EPITHELEAL CANCER | CTM ASSOCIATES, INC. (US) | 1993-05-13 | — | — | WO | disclosed |